| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 24, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its third quarter fiscal 2012 on Tuesday, May 8, 2012...
-
Apr 12, 2012
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has initiated shipments of its Guaifenesin Extended-Release Tablets, 600mg (a generic version...
-
Mar 21, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received a final "Approval for Registration" letter from the Australian Therapeutic...
-
Mar 13, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Chairman, President and CEO Joseph C. Papa will present at the Barlcays Capital Global...
-
Mar 1, 2012
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has initiated market launch and made its first shipments of minoxidil 5% foam to its retail and...
-
Feb 28, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced its Chairman & CEO Joseph Papa will present at the RBC Capital Markets' Healthcare Conference on...
-
Feb 14, 2012
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has begun shipping Loratadine-D 12 hour extended release tablets, the store brand equivalent to...
-
Feb 8, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown will present at the Leerink Swann 2012 Global Healthcare Conference on...
-
Feb 7, 2012- Fiscal second quarter revenue from continuing operations increased $121 million, or 17%, to a record $838 million
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its second quarter and six months ended December 31, 2011. Perrigo's Chairman and CEO...
-
Feb 2, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on March 20,...